(Image by Shutterstock AI Generator)
Pharmaceutical Companies Spent Nearly $4B On TV Ads Over First 8 Months Of 2025
ABC, CBS, NBC Capture Nearly Half Of All Pharma TV Ad Dollars
In A Nutshell
- Pharmaceutical companies spent $3.73 billion on TV advertising from January-August 2025, representing 14% of all TV ad spending
- While drug ads make up only 4.2% of all commercials aired, they consume 8.3% of total advertising time due to longer commercial lengths
- Weight loss drug Wegovy leads pharmaceutical TV spending at 6.31%, followed by treatments for inflammatory conditions
- ABC, CBS, and NBC capture the largest shares of pharmaceutical advertising dollars, with streaming platforms showing different patterns than traditional TV
BELLEVUE, Wash. — Pharmaceutical commercials have become a regular part of the American television experience. New data shows just how significant this presence has become: drug companies invested $3.73 billion in national TV advertising from January through August 2025, representing 14% of all television advertising spending during this period.
According to data from iSpot.TV, the pharmaceutical industry generated 278.93 billion household TV impressions (6.1% of all TV viewing), from 1.35 million individual commercials (4.2% of all ads aired), consuming 1.15 million minutes of airtime (8.3% of total TV advertising time).
The disparity between these percentages reveals an important pattern: while pharmaceutical ads represent only 4.2% of all commercials aired, they consume 8.3% of total advertising time. This indicates that drug companies purchase longer commercials on average compared to other industries.
Weight Loss Medications Lead TV Advertising Spending
Wegovy, a weight loss medication, leads all prescription drugs in TV advertising spend with 6.31% of the industry’s total investment. Following Wegovy are treatments for inflammatory conditions: Tremfya for inflammatory bowel diseases captures 3.86% of spending, and SKYRIZI for the same conditions takes 3.81%. SKYRIZI appears twice in the top rankings, also claiming 3.12% for its psoriasis treatment.
Other major spenders include Ozempic for diabetes (2.96%), RINVOQ for inflammatory bowel diseases (2.87%), Dupixent for eczema (2.84%), REXULTI for depression (2.73%), Jardiance for diabetes (2.63%), and RINVOQ for arthritis (2.49%).
These top 10 brands account for one-third of all pharmaceutical TV advertising spending. Most of these medications cost thousands of dollars annually, representing what the industry calls specialty medications that target specific conditions with smaller patient populations but higher price points.
Streaming services show different pharmaceutical advertising patterns compared to traditional television. Zepbound, another weight loss medication, captures 4.12% of pharmaceutical advertising on streaming platforms compared to 1.33% on traditional TV.
Other medications like SKYRIZI for inflammatory bowel diseases and Dupixent for asthma maintain similar advertising levels across both traditional TV and streaming platforms, while some drugs like Ebglyss show higher streaming performance.
Major TV Networks Capture Most Pharmaceutical Spending
TV advertising is an obvious gold mine for drug companies, and a windfall for certain networks. The latest data on pharmaceutical ad spending show a clear pecking order among networks, with the top ten pulling in millions more than the rest.
Traditional broadcast networks continue to receive the largest share of pharmaceutical advertising dollars. ABC leads with 16.91% of drug company TV spending, followed by CBS at 15.46% and NBC at 14.73%. FOX captures 5.15%, while ESPN receives 2.44%.
Other networks collectively account for 45.31% of spending, with Fox News (1.92%), TBS (1.91%), HGTV (1.85%), Food Network (1.79%), and TNT (1.64%) among the next tier of recipients.
High-Priced Specialty Drugs Drive TV Advertising Investment
The concentration of TV advertising among expensive specialty medications reflects how pharmaceutical companies market their newest treatments. These drugs often target smaller patient populations but command premium prices, sometimes exceeding $50,000 per year.
This distribution shows that pharmaceutical companies still believe in the power of broad-reaching television programming to deliver their messages to mass audiences. It’s particularly the case older viewers who are more likely to need prescription medications and who continue to watch significant amounts of traditional television.
Many of these conditions were previously difficult to treat effectively. The takeaway is clear: conditions with long-term treatment potential and high lifetime customer value are the ones most aggressively marketed.
Data Source: This analysis by iSpot.TV examined pharmaceutical advertising data from January 1 through August 31, 2025, tracking national linear TV advertising spending, household TV impressions, ad airings, and advertising minutes. The research covered prescription pharmaceutical industry advertising across major television networks and compared performance between traditional linear TV and streaming platforms. All data sourced from iSpot advertising analytics.
There is no way that the phamacutical industry would invest the millions of dollars that they do unless there’s a huge return on their investment.
One of the loudest claims from DTC critics is that these ads push patients to demand drugs they don’t need. It’s an easy soundbite, but it ignores reality.
Research has shown that DTC advertising primarily raises awareness of conditions and treatment options. Patients rarely walk into a doctor’s office and demand a specific drug without a conversation or clinical guidance. Physicians remain the gatekeepers—no prescription is written unless a doctor determines it’s medically appropriate.
In fact, many patients exposed to DTC ads don’t end up asking for the drug at all. What they do is bring up their symptoms, leading to earlier diagnosis, appropriate treatment, and sometimes non-pharmaceutical interventions. That’s not a prescription mill; that’s informed healthcare.